Dermatologist and gastroenterologist awareness of the potential of immunosuppressants used to treat inflammatory bowel disease to cause non-melanoma skin cancer

International Journal of Dermatology

Volumn 52, Issue 8, 2013, Pages 955-959

  De Luca, Jacqueline F ^a   Severino, Richard ^b   Lee, Yun Sun ^c   Johnson, Douglas ^b  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ARTICLE; AWARENESS; DERMATOLOGIST; DISEASE ASSOCIATION; DRUG INDUCED CANCER; ENTERITIS; GASTROENTEROLOGIST; HUMAN; NON MELANOMA SKIN CANCER; PHYSICIAN; PROFESSIONAL KNOWLEDGE; SPECIALIZATION; UNITED STATES;

DERMATOLOGY; GASTROENTEROLOGY; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; ORGAN TRANSPLANTATION; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; RISK FACTORS; SKIN NEOPLASMS;

EID: 84880698121     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2012.5612.x     Document Type: Article

References (35)

1. Mayberry JF, Judd D, Smart H, et al. Crohn's disease in Jewish people - an epidemiological study in south-east Wales. Digestion 1986; 35: 237-240.
2. Katz JA. Treatment of inflammatory bowel disease with corticosteroids. Gastroenterol Clin North Am 2004; 33: 171-189.
3. Schroll S, Sarlette A, Ahrens K, et al. Effects of azathioprine and its metabolites on repair mechanisms of the intestinal epithelium in vitro. Regul Pept 2005; 131: 1-11.
4. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ Tlymphocytes. J Clin Invest 2003; 111: 1133-1145.
5. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002; 359: 1541-1549.
6. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008; 14: 354-377.
7. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67.
8. Karagas MR, Nelson HH, Sehr P, et al. Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst 2006; 98: 389-395.
9. Harwood CA, Proby CM. Human papillomaviruses and non-melanoma skin cancer. Curr Opin Infect Dis 2002; 15: 101-114.
10. Michel G, Kemeny L, Peter RU, et al. Interleukin-8 receptor-mediated chemotaxis of normal human epidermal cells. FEBS Lett 1992; 305: 241-243.
11. Gillitzer R, Goebeler M. Chemokines in cutaneous wound healing. J Leukoc Biol 2001; 69: 513-521.
12. Akgül B, Bostanci N, Westphal K, et al. Human papillomavirus 5 and 8 E6 downregulate interleukin-8 secretion in primary human keratinocytes. J Gen Virol 2010; 91: 888-892.
13. O'Donovan P, Perret CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871-1874.
14. De Graaf YGL, Rebel H, Elghalbzouri A, et al. More epidermal p53 patches adjacent to skin carcinomas in renal transplant recipients than in immunocompetent patients: the role of azathioprine. Exp Dermatol 2008; 17: 349-355.
15. Kelly GE, Meikle W, Sheil AG. Effects of immunosuppressive therapy on the induction of skin tumors by ultraviolet irradiation in hairless mice. Transplantation 1987; 44: 429-434.
16. Canning MT, Nay SL, Pena AV, Yarosh DB. Calcineurin inhibitors reduce nuclear localization of transcription factor NFAT in UV-irradiated keratinocytes and reduce DNA repair. J Mol Histol 2006; 37: 285-291.
17. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5-year cohort study. J Invest Dermatol 2003; 120: 211-216.
18. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905-913.
19. Buell A, Hanaway M, Thomas M, et al. Skin cancer following transplantation: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc 2005; 37: 962-963.
20. Ramsay HM, Reece SM, Fryer AA, et al. Seven-year prospective study of non-melanoma skin cancer incidence in UK renal transplant recipients. Transplantation 2007; 84: 437-439.
21. Ulrich C, Schmook T, Sachse M, et al. Comparative epidemiology and pathogenic factors for non-melanoma skin cancer in organ transplant patients. Dermatol Surg 2004; 30: 622-627.
22. Harden P, Fryer A, Reece S, et al. Annual incidence and predicted risk of non-melanoma skin cancer in renal transplant recipients. Transplant Proc 2001; 33: 1302-1304.
23. Bordea C, Wojnarowska F, Millard PR, et al. Skin cancers in renal transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation 2004; 77: 574-579.
24. Ramsay HM, Fryer AA, Hawley CM, et al. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002; 147: 950-956.
25. Bouwes-Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia: a follow-up study. Transplantation 1996; 61: 715-721.
26. Bavinck JN, De Boer A, Vermeer BJ, et al. Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. Br J Dermatol 1993; 129: 242-249.
27. Ramsay HM, Fryer AA, Reece S, et al. Clinical risk factors associated with non-melanoma skin cancer in renal transplant recipients. Am J Kid Dis 2000; 36: 167-176.
28. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-1691.
29. Webb MC, Compton F, Andrews PA, Koffman CG. Skin tumors post-transplantation: a retrospective analysis of 28years' experience at a single center. Transplant Proc 1997; 29: 828-830.
30. Ekbom A, Helmick C, Zack M, et al. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991; 67: 2015-2019.
31. Mellemkjaer L, Olsen JH, Frisch M, et al. Cancer in patients with ulcerative colitis. Int J Cancer 1995; 60: 330-333.
32. Jess T, Winther KV, Munkholm P, et al. Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 2004; 19: 287-293.
33. Pedersen N, Duricova D, Elkjaer M, et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 2010; 105: 1480-1487.
34. Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010; 8: 268-274.
35. Marquez C, Bair S, Smithberger E, et al. Systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients. J Drugs Dermatol 2010; 9: 753-758.